Villejuif
France
Gustave Roussy - Drug Development Department (DITEP)
Burkitt lymphoma, guidelines, tumour lysis syndrome
T-cell engager, infections, haematological malignancy, solid tumour
diffuse large B cell lymphoma, EZH2, phase II
Lymphoma large B-cell diffuse, Molecular sequencing, Prognosis biomarker, Genetic cluster analysis, Guanine nucleotide binding protein (G protein) alpha 13 human
G-CODE, geriatric assessment, phase 1 clinical trials, older adults, feasibility, Toxicity
MAK683, EED, PRC2, DLBCL, ES, dose-escalation